Comparing two methods for removing large colorectal adenomas
Official title: Cold Snare Endoscopic Mucosal Resection vs Cold Snare Endoscopic Mucosal Resection With Adjuvant Thermal Therapy to Resection Margins - A Randomised Controlled Trial
Run by Western Sydney Local Health District · NCT05041478 · Data updated 2026-11-12
This study is testing whether a new method that combines two techniques for removing large colorectal adenomas during colonoscopy works better than using just one of the techniques alone for patients with these types of growths.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Western Sydney Local Health District Academic / other |
| Locations | 1 site (Westmead, New South Wales) |
| Status | Recruiting |
| Started | September 19, 2023 |
| Main results expected | October 1, 2028 |
| Study ends | October 1, 2028 |
| Registry record updated | March 27, 2025 |
| Trial ID | NCT05041478 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 years old with specific types of laterally spreading adenomas located in the colon or rectum.
✕Probably not a fit
Patients with bleeding disorders, pregnancy, or those with certain types of lesions or concurrent colorectal cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial is a randomized controlled trial that compares cold snare endoscopic mucosal resection (EMR) with cold snare EMR combined with margin snare tip soft coagulation (STSC) for the complete resection of 15-40mm lateral-spreading adenomas. The study aims to evaluate the safety and efficacy of these two techniques, focusing on complete resection rates and adenoma recurrence. Participants will be patients undergoing colonoscopy who have specific types of adenomas, and the trial will assess the outcomes of the different intervention methods. The hypothesis is that the combination of cold snare EMR with STSC will yield better results than cold snare EMR alone.
Why it matters
Potential benefit: If successful, this study could lead to improved safety and efficacy in the removal of large colorectal adenomas, reducing recurrence rates.
How similar studies have gone: While conventional EMR has been well-established, this specific comparison of cold snare EMR with and without STSC is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any patient undergoing colonoscopy who is older than 18 years of age, has a written consent for trial participation and has at least one laterally spreading lesion meeting the following description: * Localisation in the colon or rectum * Benign adenomatous surface features (Kudo III / IV, Japan NBI Expert Team (JNET) 2a) * Granular or non-granular topography * Paris classification 0-IIa/IIb +/- Is * If present, sessile component may be no greater than 10mm in size. * Polyp size ranging from 15 to 40mm Exclusion Criteria: * Current use of antiplatelet (excluding aspirin) or anticoagulants which have not appropriately been interrupted according to the guidelines. * Known bleeding disorder or coagulopathy. * Pregnancy * History of inflammatory bowel disease * Previously attempted or otherwise non-lifting lesions * Endoscopic features suggestive of submucosal invasion (Kudo Vi/n, JNET 2b / 3) or concurrent colorectal cancer * Lesions involving the ileocaecal valve (ICV), appendiceal oriface or anorectal junction (ARJ)
Where it's running
-
Westmead Endoscopy Unit
Westmead, New South Wales, Australia Recruiting
Study contacts
- Principal investigator: Michael Bourke, MBBS — Westmead Hospital (WSLHD)
- Study coordinator: Michael Bourke, MBBS
- Email: michael@citywestgastro.com.au
- Phone: 88905555
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
LTZ-232: a first-in-human test in advanced colorectal and other solid tumors
A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.
-
ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer
This study tests whether tracking ctDNA can guide neoadjuvant immunotherapy and surgical decisions for people with dMMR/MSI-H colon cancer, using PD-1 inhibitors first and adding CTLA-4 inhibitors if ctDNA remains detectable.
-
Tafolecimab with chemoimmunotherapy as neoadjuvant treatment for locally advanced colon cancer
This study tests whether adding tafolecimab to a chemoimmunotherapy regimen helps shrink locally advanced colon cancer before surgery in adults who have pMMR/MSS tumors.
-
Neoadjuvant pembrolizumab and porustobart for resectable MSS colon cancer
This trial tests whether giving pembrolizumab with porustobart before surgery can shrink MSS colon cancer and improve outcomes, comparing one versus two doses of porustobart.
-
DEM301 in advanced colorectal cancer: a first-in-human test
This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.
-
SHY-ONC6: a new anti-cancer drug tested in adults with advanced solid tumors
This early-phase study tests SHY-ONC6 to see if it is safe and can help people with advanced solid tumors after standard therapies have failed.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.